.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Regulatory Exclusivity Expiring in 2018

« Back to Dashboard
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Exclusivity Expiration Patented / Exclusive Use
Eli Lilly And Co
BASAGLAR
insulin glargine
SOLUTION;SUBCUTANEOUS205692-001Dec 16, 2015RXNo<disabled>NEW PRODUCT
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-002Nov 20, 2008RXNo<disabled>PEDIATRIC EXCLUSIVITY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXNo<disabled>PEDIATRIC EXCLUSIVITY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc